S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:AGLE

Aeglea BioTherapeutics - AGLE Stock Forecast, Price & News

$0.50
+0.01 (+2.86%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$0.48
$0.52
50-Day Range
$0.35
$1.27
52-Week Range
$0.34
$4.50
Volume
232,300 shs
Average Volume
378,965 shs
Market Capitalization
$31.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.88

Aeglea BioTherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
272.0% Upside
$1.88 Price Target
Short Interest
Healthy
0.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Aeglea BioTherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.01) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

225th out of 1,025 stocks

Pharmaceutical Preparations Industry

101st out of 498 stocks

AGLE stock logo

About Aeglea BioTherapeutics (NASDAQ:AGLE) Stock

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Short Interest Update
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Recap: Aeglea BioTherapeutics Q3 Earnings
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Company Calendar

Last Earnings
11/04/2021
Today
2/05/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.88
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+272.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-65,800,000.00
Net Margins
-1,471.82%
Pretax Margin
-1,474.87%

Debt

Sales & Book Value

Annual Sales
$18.74 million
Book Value
$1.70 per share

Miscellaneous

Free Float
57,513,000
Market Cap
$31.00 million
Optionable
Optionable
Beta
1.63

Key Executives

  • Jeffrey M. Goldberg
    President, Chief Executive Officer & Director
  • Jonathan D. AlspaughJonathan D. Alspaugh
    Chief Financial & Accounting Officer
  • Scott W. Rowlinson
    Vice President-Research
  • Linda Neuman
    Chief Medical Officer
  • Mark Bechter
    Vice President-Medical Affairs













AGLE Stock - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AGLE shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price forecast for 2023?

5 brokers have issued twelve-month target prices for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.88 in the next year. This suggests a possible upside of 272.0% from the stock's current price.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How have AGLE shares performed in 2023?

Aeglea BioTherapeutics' stock was trading at $0.4499 at the beginning of 2023. Since then, AGLE shares have increased by 12.0% and is now trading at $0.5040.
View the best growth stocks for 2023 here
.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 604,200 shares, a decrease of 39.6% from the December 31st total of 1,000,000 shares. Based on an average daily volume of 1,950,000 shares, the days-to-cover ratio is currently 0.3 days.
View Aeglea BioTherapeutics' Short Interest
.

When is Aeglea BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our AGLE earnings forecast
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.03. The biotechnology company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.38 million. Aeglea BioTherapeutics had a negative net margin of 1,471.82% and a negative trailing twelve-month return on equity of 114.95%.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony G Quinn, Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends
.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $0.50.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $31.00 million and generates $18.74 million in revenue each year. The biotechnology company earns $-65,800,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

The company employs 101 workers across the globe.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.

This page (NASDAQ:AGLE) was last updated on 2/6/2023 by MarketBeat.com Staff